×
About 2,198 results

ALLMedicine™ Anovulation Center

Research & Reviews  1,033 results

The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary sy...
https://doi.org/10.1038/s41467-021-21308-y 10.1016/j.fertnstert.2011.09.024 10.1016/j.tem.2019.04.006 10.1089/obe.2007.0019 10.1080/17446651.2019.1576522 10.1371/journal.pgen.1007813 10.1530/REP-19-0197 10.1038/s41591-018-0035-5 10.1038/s41591-019-0666-1 10.1016/j.molmet.2020.01.001 10.1093/humrep/dex036 10.1620/tjem.119.85 10.1038/laban.980 10.1016/j.diabres.2017.06.011 10.1210/jc.2013-2350 10.1038/nrdp.2016.57 10.2337/db07-0706 10.1016/S0002-9343(01)00948-2 10.1016/j.fertnstert.2017.10.018 10.1152/ajpendo.00501.2007 10.1097/OGX.0000000000000661 10.1016/j.fertnstert.2017.11.017 10.1530/REP-18-0120 10.1177/1933719116670265 10.1210/jc.2010-1290 10.1016/j.tem.2009.06.003 10.1111/j.1365-2265.2009.03645.x 10.1016/j.steroids.2013.05.001 10.1016/S0140-6736(03)14410-8 10.1210/jc.2006-1422 10.1095/biolreprod38.4.780 10.1016/0026-0495(92)90175-A 10.1016/S0015-0282(97)00473-1 10.1210/jc.2008-0714 10.1210/en.2014-1185 10.1155/2018/4315413 10.1093/humupd/dmn015 10.1016/S0015-0282(97)81417-3 10.1038/ncomms10055 10.1210/jc.2008-1231 10.1093/humrep/des460 10.1210/jc.2017-00308 10.1093/humrep/dep225 10.1016/j.fertnstert.2018.09.022 10.1016/j.psyneuen.2016.08.005 10.1515/jpem-2012-0047 10.1210/jc.2006-2012 10.1080/00016340802478166 10.1016/j.jpeds.2018.09.064 10.1016/j.fertnstert.2018.10.011 10.1093/humrep/der435 10.1210/en.2008-1612 10.1016/j.rbmo.2018.05.011 10.1016/j.fertnstert.2018.11.028 10.1016/j.rbmo.2019.03.203 10.1210/jc.2019-00383 10.1016/j.ejogrb.2012.10.015 10.1385/ENDO:19:1:65 10.1080/09513590.2017.1412429 10.4103/0974-1208.158616 10.1016/S0015-0282(99)00090-4 10.1073/pnas.1708854114 10.1095/biolreprod63.5.1245
Nature Communications; Bourgneuf C, Bailbé D et. al.

Feb 17th, 2021 - Polycystic ovary syndrome (PCOS) is characterized by an oligo-anovulation, hyperandrogenism and polycystic ovarian morphology combined with major metabolic disturbances. However, despite the high prevalence and the human and economic consequences ...

Revisiting the serum level of anti-Müllerian hormone in patients with functional hypoth...
https://doi.org/10.1093/humrep/deab024
Human Reproduction (Oxford, England); Makolle S, Catteau-Jonard S et. al.

Feb 13th, 2021 - Are serum levels of anti-Müllerian hormone (AMH) normal in patients with functional hypothalamic anovulation (FHA)? Our study confirms that in the general FHA population, serum AMH levels are not decreased, but if patients with polycystic ovarian ...

Role of the total progressive motile sperm count (TPMSC) in different infertility facto...
https://doi.org/10.1136/bmjopen-2020-040563
BMJ Open; Lin H, Li Y et. al.

Feb 7th, 2021 - The objective of this retrospective cohort study was to explore the optimal range of the total progressive motile sperm count (TPMSC) for live birth in couples with varying infertility diagnosis undergoing intrauterine insemination (IUI) in a univ...

Hyperandrogenic Anovulation: Differential Diagnosis and Evaluation.
https://doi.org/10.1016/j.ecl.2020.12.003
Endocrinology and Metabolism Clinics of North America; Wierman ME

Feb 1st, 2021 - Hyperandrogenic anovulation refers to the constellation of disorders that present in women with irregular menses, hirsutism and/or acne across the lifespan. Understanding the clinical signs and symptoms of each diagnosis in the differential and la...

Effects of Environment and Lifestyle Factors on Anovulatory Disorder.
https://doi.org/10.1007/978-981-33-4187-6_5 10.1093/humrep/deq275 10.1007/978-3-319-31973-5 10.1093/humupd/dmw027 10.1016/bs.vh.2018.01.013 10.1186/s12929-018-0438-0 10.1016/j.ydbio.2017.06.029 10.1186/s13048-016-0246-7 10.1530/REP-17-0015 10.1210/er.2014-1020 10.1016/j.fertnstert.2014.11.015 10.1530/REP-19-0494 10.1210/jc.2017-00131 10.3389/fendo.2018.00123 10.1507/endocrj.EJ18-0026 10.5603/EP.2015.0033 10.1007/s40618-019-01013-w 10.3390/biomedicines7010005 10.5114/pm.2018.78550 10.1159/000444770 10.1038/s41580-018-0074-2 10.1016/j.tree.2018.12.002 10.1126/science.1237190 10.1152/physiol.00037.2017 10.1016/j.coemr.2019.12.003 10.1023/B:CANC.0000031769.14728.bc 10.1016/j.jrras.2015.03.003 10.1016/j.freeradbiomed.2016.12.008 10.1016/j.freeradbiomed.2013.07.024 10.1200/JCO.2017.76.3441 10.1556/ABiol.65.2014.1.3 10.1016/S0015-0282(16)49268-X 10.1093/humrep/deg016 10.1016/j.semradonc.2017.04.010 10.3892/ijo.2017.4046 10.1080/10934529.2017.1383124 10.1186/s12958-018-0391-5 10.1016/j.etap.2017.02.024 10.1016/j.coemr.2019.06.007 10.1007/s00018-019-03028-1 10.1016/j.mehy.2017.03.025 10.1007/s00204-016-1866-9 10.1016/j.rbmo.2014.06.013 10.1016/j.reprotox.2012.02.005 10.1073/pnas.1207854109 10.1186/s12940-017-0242-4 10.1016/j.etap.2014.10.015 10.1016/j.mce.2018.02.007 10.1016/j.fertnstert.2016.06.027 10.1016/j.obmed.2019.100090 10.1080/09513590.2019.1630608 10.1016/j.cca.2020.05.009 10.1016/j.taap.2014.02.009 10.1002/em.21847 10.1016/j.taap.2018.02.011 10.1016/j.biotechadv.2017.12.002 10.1016/j.reprotox.2012.02.006 10.1071/RD14113 10.1016/j.reprotox.2015.02.013 10.1016/j.taap.2020.114952 10.1016/j.chemosphere.2019.125206 10.1179/oeh.2006.12.3.260 10.1016/j.envres.2011.09.009 10.1016/j.reprotox.2016.02.009 10.1095/biolreprod.114.122606 10.1016/j.mce.2017.08.015 10.3389/fendo.2019.00346 10.1152/physrev.00023.2015 10.1016/j.metabol.2020.154229 10.1016/j.fertnstert.2018.05.027 10.1186/1477-7827-11-1 10.1097/01.AOG.0000287293.25465.e1 10.1016/j.ajog.2017.08.010 10.1016/j.fertnstert.2017.01.017 10.1016/j.jnutbio.2017.01.003 10.1016/j.metabol.2020.154193 10.1016/j.jchemneu.2014.08.008 10.1186/s12958-018-0336-z 10.1007/978-981-15-1792-1_8 10.1093/humrep/13.6.1502 10.1016/j.metabol.2018.11.002 10.1111/cob.12258 10.1007/s40279-016-0669-8 10.1111/jog.13614 10.1007/s11914-017-0412-x 10.1016/j.fertnstert.2018.06.016 10.1016/j.reprotox.2017.06.184 10.1016/j.taap.2013.05.009 10.2105/AJPH.84.9.1429 10.1186/s40738-017-0037-x 10.1503/cmaj.181577 10.1021/acschemneuro.8b00117 10.1016/S1071-5576(01)00133-2 10.1016/j.psyneuen.2018.09.031 10.1210/er.2016-1133 10.1016/0002-9378(86)90274-7 10.1016/j.mce.2019.110579 10.1016/j.ygcen.2015.09.010 10.1016/j.ajog.2017.11.579 10.1016/j.fertnstert.2013.02.036
Advances in Experimental Medicine and Biology; Song Y, Li R

Feb 1st, 2021 - Anovulatory disorder comprises around 30% of female infertility. The origin of ovulatory failure is rooted in pituitary FSH secretion. Any factor or process that disrupts the finely tuned interactions of hypothalamo-pituitary-ovarian axis can pote...

see more →

Guidelines  3 results

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they shoul...

Aromatase Inhibitors in Gynecologic Practice
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Aromatase-Inhibitors-in-Gynecologic-Practice
Committee on Gynecologic Practice

Jun 29th, 2018 - Aromatase inhibitors have been used for the treatment of breast cancer, ovulation induction, endometriosis, and other estrogen-modulated conditions. For women with breast cancer, bone mineral density screening is recommended with long-term aromata.

British Fertility Society. 'Ovulation induction in WHO Type 1 anovulation: Guidelines f...
https://doi.org/10.3109/14647273.2013.829673
Human Fertility (Cambridge, England); Yasmin E, Davies M et. al.

Nov 19th, 2013 - British Fertility Society. 'Ovulation induction in WHO Type 1 anovulation: Guidelines for practice'. Produced on behalf of the BFS Policy and Practice Committee.|2013|Yasmin E,Davies M,Conway G,Balen AH,British Fertility Society ,|etiology,therapy...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  1,091 results

The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary sy...
https://doi.org/10.1038/s41467-021-21308-y 10.1016/j.fertnstert.2011.09.024 10.1016/j.tem.2019.04.006 10.1089/obe.2007.0019 10.1080/17446651.2019.1576522 10.1371/journal.pgen.1007813 10.1530/REP-19-0197 10.1038/s41591-018-0035-5 10.1038/s41591-019-0666-1 10.1016/j.molmet.2020.01.001 10.1093/humrep/dex036 10.1620/tjem.119.85 10.1038/laban.980 10.1016/j.diabres.2017.06.011 10.1210/jc.2013-2350 10.1038/nrdp.2016.57 10.2337/db07-0706 10.1016/S0002-9343(01)00948-2 10.1016/j.fertnstert.2017.10.018 10.1152/ajpendo.00501.2007 10.1097/OGX.0000000000000661 10.1016/j.fertnstert.2017.11.017 10.1530/REP-18-0120 10.1177/1933719116670265 10.1210/jc.2010-1290 10.1016/j.tem.2009.06.003 10.1111/j.1365-2265.2009.03645.x 10.1016/j.steroids.2013.05.001 10.1016/S0140-6736(03)14410-8 10.1210/jc.2006-1422 10.1095/biolreprod38.4.780 10.1016/0026-0495(92)90175-A 10.1016/S0015-0282(97)00473-1 10.1210/jc.2008-0714 10.1210/en.2014-1185 10.1155/2018/4315413 10.1093/humupd/dmn015 10.1016/S0015-0282(97)81417-3 10.1038/ncomms10055 10.1210/jc.2008-1231 10.1093/humrep/des460 10.1210/jc.2017-00308 10.1093/humrep/dep225 10.1016/j.fertnstert.2018.09.022 10.1016/j.psyneuen.2016.08.005 10.1515/jpem-2012-0047 10.1210/jc.2006-2012 10.1080/00016340802478166 10.1016/j.jpeds.2018.09.064 10.1016/j.fertnstert.2018.10.011 10.1093/humrep/der435 10.1210/en.2008-1612 10.1016/j.rbmo.2018.05.011 10.1016/j.fertnstert.2018.11.028 10.1016/j.rbmo.2019.03.203 10.1210/jc.2019-00383 10.1016/j.ejogrb.2012.10.015 10.1385/ENDO:19:1:65 10.1080/09513590.2017.1412429 10.4103/0974-1208.158616 10.1016/S0015-0282(99)00090-4 10.1073/pnas.1708854114 10.1095/biolreprod63.5.1245
Nature Communications; Bourgneuf C, Bailbé D et. al.

Feb 17th, 2021 - Polycystic ovary syndrome (PCOS) is characterized by an oligo-anovulation, hyperandrogenism and polycystic ovarian morphology combined with major metabolic disturbances. However, despite the high prevalence and the human and economic consequences ...

Revisiting the serum level of anti-Müllerian hormone in patients with functional hypoth...
https://doi.org/10.1093/humrep/deab024
Human Reproduction (Oxford, England); Makolle S, Catteau-Jonard S et. al.

Feb 13th, 2021 - Are serum levels of anti-Müllerian hormone (AMH) normal in patients with functional hypothalamic anovulation (FHA)? Our study confirms that in the general FHA population, serum AMH levels are not decreased, but if patients with polycystic ovarian ...

Role of the total progressive motile sperm count (TPMSC) in different infertility facto...
https://doi.org/10.1136/bmjopen-2020-040563
BMJ Open; Lin H, Li Y et. al.

Feb 7th, 2021 - The objective of this retrospective cohort study was to explore the optimal range of the total progressive motile sperm count (TPMSC) for live birth in couples with varying infertility diagnosis undergoing intrauterine insemination (IUI) in a univ...

Hyperandrogenic Anovulation: Differential Diagnosis and Evaluation.
https://doi.org/10.1016/j.ecl.2020.12.003
Endocrinology and Metabolism Clinics of North America; Wierman ME

Feb 1st, 2021 - Hyperandrogenic anovulation refers to the constellation of disorders that present in women with irregular menses, hirsutism and/or acne across the lifespan. Understanding the clinical signs and symptoms of each diagnosis in the differential and la...

Effects of Environment and Lifestyle Factors on Anovulatory Disorder.
https://doi.org/10.1007/978-981-33-4187-6_5 10.1093/humrep/deq275 10.1007/978-3-319-31973-5 10.1093/humupd/dmw027 10.1016/bs.vh.2018.01.013 10.1186/s12929-018-0438-0 10.1016/j.ydbio.2017.06.029 10.1186/s13048-016-0246-7 10.1530/REP-17-0015 10.1210/er.2014-1020 10.1016/j.fertnstert.2014.11.015 10.1530/REP-19-0494 10.1210/jc.2017-00131 10.3389/fendo.2018.00123 10.1507/endocrj.EJ18-0026 10.5603/EP.2015.0033 10.1007/s40618-019-01013-w 10.3390/biomedicines7010005 10.5114/pm.2018.78550 10.1159/000444770 10.1038/s41580-018-0074-2 10.1016/j.tree.2018.12.002 10.1126/science.1237190 10.1152/physiol.00037.2017 10.1016/j.coemr.2019.12.003 10.1023/B:CANC.0000031769.14728.bc 10.1016/j.jrras.2015.03.003 10.1016/j.freeradbiomed.2016.12.008 10.1016/j.freeradbiomed.2013.07.024 10.1200/JCO.2017.76.3441 10.1556/ABiol.65.2014.1.3 10.1016/S0015-0282(16)49268-X 10.1093/humrep/deg016 10.1016/j.semradonc.2017.04.010 10.3892/ijo.2017.4046 10.1080/10934529.2017.1383124 10.1186/s12958-018-0391-5 10.1016/j.etap.2017.02.024 10.1016/j.coemr.2019.06.007 10.1007/s00018-019-03028-1 10.1016/j.mehy.2017.03.025 10.1007/s00204-016-1866-9 10.1016/j.rbmo.2014.06.013 10.1016/j.reprotox.2012.02.005 10.1073/pnas.1207854109 10.1186/s12940-017-0242-4 10.1016/j.etap.2014.10.015 10.1016/j.mce.2018.02.007 10.1016/j.fertnstert.2016.06.027 10.1016/j.obmed.2019.100090 10.1080/09513590.2019.1630608 10.1016/j.cca.2020.05.009 10.1016/j.taap.2014.02.009 10.1002/em.21847 10.1016/j.taap.2018.02.011 10.1016/j.biotechadv.2017.12.002 10.1016/j.reprotox.2012.02.006 10.1071/RD14113 10.1016/j.reprotox.2015.02.013 10.1016/j.taap.2020.114952 10.1016/j.chemosphere.2019.125206 10.1179/oeh.2006.12.3.260 10.1016/j.envres.2011.09.009 10.1016/j.reprotox.2016.02.009 10.1095/biolreprod.114.122606 10.1016/j.mce.2017.08.015 10.3389/fendo.2019.00346 10.1152/physrev.00023.2015 10.1016/j.metabol.2020.154229 10.1016/j.fertnstert.2018.05.027 10.1186/1477-7827-11-1 10.1097/01.AOG.0000287293.25465.e1 10.1016/j.ajog.2017.08.010 10.1016/j.fertnstert.2017.01.017 10.1016/j.jnutbio.2017.01.003 10.1016/j.metabol.2020.154193 10.1016/j.jchemneu.2014.08.008 10.1186/s12958-018-0336-z 10.1007/978-981-15-1792-1_8 10.1093/humrep/13.6.1502 10.1016/j.metabol.2018.11.002 10.1111/cob.12258 10.1007/s40279-016-0669-8 10.1111/jog.13614 10.1007/s11914-017-0412-x 10.1016/j.fertnstert.2018.06.016 10.1016/j.reprotox.2017.06.184 10.1016/j.taap.2013.05.009 10.2105/AJPH.84.9.1429 10.1186/s40738-017-0037-x 10.1503/cmaj.181577 10.1021/acschemneuro.8b00117 10.1016/S1071-5576(01)00133-2 10.1016/j.psyneuen.2018.09.031 10.1210/er.2016-1133 10.1016/0002-9378(86)90274-7 10.1016/j.mce.2019.110579 10.1016/j.ygcen.2015.09.010 10.1016/j.ajog.2017.11.579 10.1016/j.fertnstert.2013.02.036
Advances in Experimental Medicine and Biology; Song Y, Li R

Feb 1st, 2021 - Anovulatory disorder comprises around 30% of female infertility. The origin of ovulatory failure is rooted in pituitary FSH secretion. Any factor or process that disrupts the finely tuned interactions of hypothalamo-pituitary-ovarian axis can pote...

see more →

News  69 results

ACOG advises bleeding disorder screening for teens with heavy menstruation
https://www.mdedge.com/obgyn/article/207161/gynecology/acog-advises-bleeding-disorder-screening-teens-heavy-menstruation?channel=27970
Heidi Splete

Aug 27th, 2019 - Adolescent girls with heavy menstrual bleeding should be assessed for bleeding disorders, according to a Committee Opinion issued by the American College of Obstetricians and Gynecologists. A bleeding disorder is secondary only to anovulation as a.

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding: ACOG COMMITTEE OPINION, Number 785
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-Bleeding-Disorders-in-Adolescents-With-Heavy-Menstrual-Bleeding

Aug 21st, 2019 - Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they shoul...

Medical Treatment of Fibroids and Related Heavy Menstrual Bleeding
https://www.staging.medscape.com/viewarticle/904787

Nov 18th, 2018 - Uterine Fibroids and Heavy Menstrual Bleeding A typical menstruation occurs every 21-35 days (typically around 28 days) and lasts for 2-7 days. Excessive bleeding (heavy flow, clots) or menstruation that lasts longer than 7 days could cause anemia...

Medical Treatment of Fibroids and Related Heavy Menstrual Bleeding
https://www.medscape.com/viewarticle/904787

Nov 18th, 2018 - Uterine Fibroids and Heavy Menstrual Bleeding A typical menstruation occurs every 21-35 days (typically around 28 days) and lasts for 2-7 days. Excessive bleeding (heavy flow, clots) or menstruation that lasts longer than 7 days could cause anemia...

Gonadotropins succeed where clomifene fails
https://www.mdedge.com/endocrinology/article/156634/reproductive-endocrinology/gonadotropins-succeed-where-clomifene-fails
Heidi Splete

Jan 20th, 2018 - Switching to gonadotropins increased the odds of live births for women with normogonadotropic anovulation with little success for continuing with clomifene citrate, based on data from 666 women. Women who have not become pregnant after six cycles.

see more →